Background Ovarian cancer is the sixth most common cancer in women world‐wide.
Epithelial ovarian cancer (EOC) is the most common; three‐quarters of women present …

Background Ovarian cancer is the sixth most common cancer in women world‐wide.
Epithelial ovarian cancer (EOC) is the most common; three‐quarters of women present …

Background Poly-ADP-ribose polymerase (PARP) inhibitors have emerged as a novel class
of therapeutics for ovarian cancer (OC); however, PARP inhibitors present a class effect …

Background Ovarian cancer is the sixth most common cancer and seventh most common
cause of cancer death in women world‐wide. Three‐quarters of women present when the …

Objective This study aims to compare the efficacy and safety of different poly (ADP-ribose)
polymerase (PARP) inhibitors in patients with ovarian cancer through a network meta …

Background The purpose of this study was to explore the efficacy and tolerability of poly
ADP-ribose polymerase (PARP) inhibitors in patients with ovarian cancer. Methods The …

PURPOSE To provide recommendations on the use of poly (ADP-ribose) polymerase
inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer …

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline
recommendations as a response to the emergence of new and practice-changing data. The …

Background The second decade of 2000s is witnessing a new ovarian cancer (OC)
paradigm shift thanks to the results recently obtained by a new class of targeted agents: the …

Introduction Poly (ADP-ribose) polymerase (PARP) inhibitors are being developed in
maintenance and recurrence treatment settings of epithelial ovarian cancers (EOCs) with …